[Description exercise 5 Çؼ³] - ðû
[ÀܼҸ® ÇѸ¶µð]
ÀüüÀûÀ¸·Î Á» ´õ ±æ°Ô ½á º¸¼¼¿ä. ½Ç¹«¿¡¼´Â ½Ã°£ °ü°è(1½Ã°£¿¡ 4¸í, 3½Ã°£¿¡ 12¸íÀ» °Ë»çÇϱâ À§Çؼ´Â ´Ù¼Ò ¹Ù»Þ´Ï´Ù)·Î ÀÎÇØ °£´ÜÈ÷ ±â¼úÇÏ°í ÀÖÁö¸¸, DEX´Â °øºÎÇÏ°í ¿¬½ÀÇÏ´Â °úÁ¤(ùÊì»ãÁã§ñý)À̹ǷΠµÇµµ·Ï ±æ°Ô ½á º¸´Â ÆíÀÌ ÁÁ½À´Ï´Ù.
EndoTODAY ºÐ·ù¹ýÀ» ¼Ò°³ÇÕ´Ï´Ù. ³»½Ã°æ °á°ú ±â¼ú¿¡ »ç¿ëµÇ´Â ÈçÇÑ ºÐ·ù¹ýÀ» ¸ð¾ÆµÎ¾ú½À´Ï´Ù.
¼Ò°ß: Áß,ÇϺνĵµ¿¡ °ÉÃÄ ¼ö mm Á¤µµÀÇ multiple oval to linear shallow ulcerative lesionµéÀÌ ÀÖ½À´Ï´Ù. ±Ë¾çÀÇ °æ°è(edge)´Â ¸íÈ®ÇÏ°í, ¹Ù´Ú(base)Àº ÆòÆòÇϸç, ¹éȲ»öÀÇ »ïÃâ¹°·Î µ¤¿© ÀÖ½À´Ï´Ù. Áߺνĵµ¿¡¼´Â ulcerµé »çÀÌ¿¡ Á¤»ó ½Äµµ Á¡¸·µµ °üÂûµÇ¸ç ÀϺδ ÀåÃà ¹æÇâÀ¸·Î À¶ÇյǾî ÀÖ½À´Ï´Ù. ÇϺÎÂÊÀ¸·Î ³»·Á °¥¼ö·Ï ±Ë¾çÀÌ Ä¿Áö°í ´õ¿í À¶ÇյǾî Á¤»ó Á¡¸·Àº °ÅÀÇ ³²Áö ¾Ê°í ´ëºÎºÐ ulcer¿Í exudate·Î µ¤¿© ÀÖ½À´Ï´Ù.
Áø´Ü: Viral esophagitis (herpetic esophagitis, more likely)
[ÀÌÁØÇà comment]
º´¼ÒÀÇ ¸ð¾çÀ» ±â¼úÇϱⰡ ¾î·Á¿ü´ø °Í °°½À´Ï´Ù. ±Ë¾çÀ̶ó°í ºÎ¸£±â¿¡´Â ±íÁö ¾ÊÀº °Í °°°í, ¹Ì¶õÀ̶ó°í ºÎ¸£±â¿¡´Â ¾èÀº °Í °°°í, ÁÖº¯ÀÌ ÇϾé°Ô ¿Ã¶ó¿Â ¸ð¾çµµ ±â¼úÇϱⰡ ¾î·Æ°í.... ÀÌ·² ¶§¿¡´Â shallow ulcer ¶ó´Â Ç¥ÇöÀ» ½á º¸¼¼¿ä. Àú´Â ´ÙÀ½°ú °°ÀÌ ±â¼úÇØ º¸¾Ò½À´Ï´Ù. "Áß,ÇϺνĵµ¿¡ °ÉÃÄ ¼ö mm Á¤µµÀÇ multiple oval to linear shallow ulcerative lesionµéÀÌ ÀÖ½À´Ï´Ù. ±Ë¾çÀÇ °æ°è(edge)´Â ¸íÈ®ÇÏ°í, ¹Ù´Ú(base)Àº ÆòÆòÇϸç, ¹éȲ»öÀÇ »ïÃâ¹°·Î µ¤¿© ÀÖ½À´Ï´Ù. Áߺνĵµ¿¡¼´Â ulcerµé »çÀÌ¿¡ Á¤»ó ½Äµµ Á¡¸·µµ °üÂûµÇ¸ç ÀϺδ ÀåÃà ¹æÇâÀ¸·Î À¶ÇյǾî ÀÖ½À´Ï´Ù. ÇϺÎÂÊÀ¸·Î ³»·Á °¥¼ö·Ï ±Ë¾çÀÌ Ä¿Áö°í ´õ¿í À¶ÇյǾî Á¤»ó Á¡¸·Àº °ÅÀÇ ³²Áö ¾Ê°í ´ëºÎºÐ ulcer¿Í exudate·Î µ¤¿© ÀÖ½À´Ï´Ù."
Herpetic esophagitisÀÇ ¼Ò°ßÀ» °ü·ÊÀûÀ¸·Î ±Ë¾çÀ̶ó°í ±â¼úÇÏ°í ÀÖÁö¸¸ »ç½Ç ¹«Ã´ ¾î»öÇÑ Ç¥ÇöÀÔ´Ï´Ù. ¾îµð¸¦ º¸´õ¶óµµ ±íÀº ¼Õ»óÀÎ ±Ë¾ç°ú´Â ´Ù¸£°Åµç¿ä.... Àú´Â ¹Ì¶õÀ̶ó°í ¾²½Ã°í, ²À ±Ë¾çÀ̶ó°í ¾²°í ½ÍÀ¸¸é shallow ulcer¶ó´Â ¿ë¾î¸¦ ¼±ÅÃÇϵµ·Ï ±ÇÇÏ°í ÀÖ½À´Ï´Ù.
½ÄµµÁúȯ³»½Ã°æ¾ÆƲ¶ó½º 1±Ç 2È£
ÀÛÀº º´¼ÒÀÇ Å©±â¸¦ ¸î mm¶ó°í ÇϽŠºÐµµ ÀÖ°í 1-1.5cm ¶ó°í ÇϽŠºÐµµ ÀÖ¾ú½À´Ï´Ù. '½Äµµ Áö¸§Àº 2.5cm, ´ëÀå Áö¸§Àº 5cm'¸¦ ´ë°ÀÇ ±âÁØÀ¸·Î »ïÀ¸¸é ½±½À´Ï´Ù.
Á¤´äÀº herpetic esophagitisÀÔ´Ï´Ù. °£È¤ Candida esophagitis¶ó°í ´äÇÏ´Â ºÐµéÀÌ °è½Ã´Âµ¥, white plaque·Î º¸¸é Candida esophagitis¶ó°í ÇÒ ¼ö ÀÖ°ÚÀ¸³ª, ÁÖº¯ÀÌ ¾à°£ À¶±âµÈ shallow ulcerationµé·Î º¸¸é herpetic esophagitis¸¦ »ý°¢ÇÒ ¼ö ÀÖ½À´Ï´Ù.
Herpetic esophagitisÀÇ ÀüÇüÀûÀÎ ³»½Ã°æ ¼Ò°ß¿¡ ´ëÇؼ´Â ±³°ú¼¿¡´Â ÀÌ·¸°Ô ÀûÇô ÀÖ½À´Ï´Ù. (1) The endoscopic appearance is characterized by diffuse friability; ulceration; and exudates, mostly in the distal esophagus. (2) Classically, the earliest esophageal lesions are rounded 1- to 3-mm vesicles in the mid to distal esophagus, the centers of which slough to form discrete circumscribed ulcers with raised edges. (3) These lesions can also be appreciated radiographically. Àß µé¾î ¸Â½À´Ï±î?
¹ÙÀÌ·¯½º ½Äµµ¿°(CMV, herpetic)À» ¼³¸íÇϴµ¥ °¡Àå ¸¹ÀÌ ÀÌ¿ëµÇ´Â ±×¸²ÀÔ´Ï´Ù. HerpeticÀº vesicleÀ» Çü¼ºÇÏ´Ù°¡ ÅÍÁ®¼ ±Ë¾çÀÌ »ý±âÁö¸¸ ±Ë¾çÀÇ marginÀÌ ´Ù¼Ò ¿Ã¶ó¿ÍÀÖ°í ±× ºÎÀ§¿¡ ¹ÙÀÌ·¯½º°¡ À§Ä¡ÇÕ´Ï´Ù. CMV´Â À¶±âµÈ margin ¾øÀÌ °©Àڱ⠱˾çÀÌ ÀÖ°í ±Ë¾ç ¹Ù´Ú¿¡ ¹ÙÀÌ·¯½º°¡ À§Ä¡ÇÕ´Ï´Ù.
ÀÏÀü¿¡ °í½Å´ëÇб³ ¹Ú¹«ÀÎ ±³¼ö´Ô²²¼ 47ȸ ³»½Ã°æÇÐȸ ¼¼¹Ì³ª¿¡¼ ¸»¾¸ÇϽŠ¹Ù¸¦ ¿Å±é´Ï´Ù. "Ç츣Æ佺 ½Äµµ¿°(Herpetic esophagitis)ÀÇ Ãʱ⿡´Â 3-5 mm Á¤µµÀÇ ÀÛÀº ±¸Áø ¶Ç´Â ¼öÆ÷°¡ º¸À̴µ¥ ±× ÁÖº¯ºÎ´Â ¹ßÀûÀ» º¸À̳ª º´º¯ »çÀÌÀÇ Á¡¸·Àº Á¤»óÀÌ´Ù. Á¡Â÷ ÁøÇàÇÏ¸é¼ ¼öÆ÷°¡ ¹Ì¶õ ¶Ç´Â ±Ë¾çÀ¸·Î ¹ßÀüÇÑ´Ù. ±Ë¾çÀº µÕ±Û°í ÁÖº¯ºÎ¿Í °æ°è°¡ ¸íÈ®Çϸç ÁÖÀ§Á¡¸·º¸´Ù ¾à°£ À¶±âµÇ¾î ÀÖ´Ù. ±Ë¾çÀÇ ±âÀúºÎ´Â ¹éȲ»öÀÇ »ïÃâ¹°·Î µ¤¿© Àִµ¥ À¶ÇÕÇÏ¿© Å« ±Ë¾çÀ» Çü¼ºÇϱ⵵ ÇÑ´Ù. ÀÌ °æ¿ì ±Ë¾çÀº ½ÄµµÀÇ Á¾Ãà ¹æÇâÀ¸·Î »ý±â´Â °æÇâÀÌ ÀÖ´Ù."
°£È¤ ½Äµµ º´¼Ò¿Í ÇÔ²² ±¸°¿¡ Ç츣Æ佺¼º º´º¯ÀÌ ÇÔ²² ÀÖÀ¸¸é clue°¡ µË´Ï´Ù.
Ç츣Æ佺 ½Äµµ¿°°ú CMV ½Äµµ¿°À» ±¸ºÐÇϱ⠾î·ÆÁö¸¸, impression¿¡ r/o herpes, r/o CMV·Î ¾²´Â °ÍÀº ÇÇÇϽʽÿÀ. ¿µ»óÀÇÇаú ¼±»ý´ÔµéÀÌ r/o TB, r/o cancer¶ó°í ¾²´Â °Í°ú ¸¶Âù°¡ÁöÀÔ´Ï´Ù. Viral esophagitis (herpetic esophagitis, more likely)¿Í °°ÀÌ Çϳª¸¦ ¾²´Â ½À°üÀ» °¡Áý½Ã´Ù. ¿µ ¸¶À½¿¡ °É¸®¸é viral esophagitis (herpetic esophagitis, more likely; CMV esophagitis, less likely)·Î ½áµµ ÁÁ½À´Ï´Ù. ¿©ÇÏÆ° ÄÛ Áý¾î¼ Çϳª¸¦ ¾²´Â ½À°üÀÌ ÁÁ½À´Ï´Ù.
* Âü°í: EndoTODAY ¹ÙÀÌ·¯½º ½Äµµ¿°
¼Ò°ß: »óºÎ½Äµµ 5½Ã ¹æÇâ¿¡ 1cm Å©±âÀÇ Á¤»ó Á¡¸·À¸·Î µ¤ÀÎ molar tooth shapeÀÇ elevated lesionÀÌ ÀÖ½À´Ï´Ù. EUS¿¡¼ 2nd lay¿¡¼ originÇÏ´Â mixed hyperechoic lesionÀÔ´Ï´Ù.
Áø´Ü: Esophageal SET (granular cell tumor, more likely)
[ÀÌÁØÇà comment]
½Äµµ SET (SMT¶ó°í ºÒ·¯µµ ÁÁ½À´Ï´Ù)ÀÔ´Ï´Ù. ¾î±Ý´Ï ¸ð¾çÀ̹ǷΠ´ëºÎºÐ granular cell tumor¶ó°í ´äÇÏ´Â ¹®Á¦ÀÔ´Ï´Ù. Á¤´äÀº ¾Æ´ÏÁö¸¸ ³»½Ã°æÀ¸·Î´Â ±×·¸°Ô¹Û¿¡ ÇÒ ¼ö ¾ø½À´Ï´Ù. Á¶Á÷°Ë»ç°¡ ²À ÇÊ¿äÇÑ Áõ·ÊÀÔ´Ï´Ù.
Á¤´äÀº large cell neuroendocrine carcinoma¿´½À´Ï´Ù. ³»½Ã°æ°ú EUS ¼Ò°ß¸¸À¸·Î Á¤È®ÇÑ Áø´ÜÀ» ¸ÂÃâ ¼ö ¾ø´Â °ÍÀº ´ç¿¬ÇÑ ÀÏÀÔ´Ï´Ù. Á¶Á÷°Ë»çµµ neuroendocrine tumor ÀÎ °Í±îÁö¸¸ ¾Ë·ÁÁÖ°í, neuroendocrine carcinomaÀÎ °ÍÀº ESD ÈÄ ¾Ë°Ô µÇ¾ú½À´Ï´Ù. ÀϹÝÀûÀÎ granular cell tumor¿Í ´Ù¸¥ Á¡À» ¤¾îº»´Ù¸é... »öÁ¶ Á¤µµ¸¦ ¸»ÇÒ ¼ö ÀÖ°Ú½À´Ï´Ù. Granular cell tumor´Â Á» ´õ ³ë¶þ°Ô ºñÃÄ º¸À̴ϱî¿ä. ÇÑ ¼±»ý´Ô²²¼ neuroendocrine carcinoma¸¦ »ý°¢Çϼ̽À´Ï´Ù. Á¤´äÀ» Á¦½ÃÇÑ Á¡Àº ÁÁ±â´Â ÇÑÁö¸¸, ÀϹÝÀûÀÎ °ÍÀ» ¸ÕÀú ¶°¿Ã¸®´Â °ÍÀÌ ÀÚ¿¬½º·¯¿ï °Í °°½À´Ï´Ù.
Á¶Á÷°Ë»ç¿¡¼ neuroendocrine tumor·Î ³ª¿Í ESD¸¦ ÇÏ¿© large cell neuroendocrine carcinoma with submucosal and lymphatic invasionÀ¸·Î ³ª¿Í ¼ö¼úÀ» ±ÇÇß½À´Ï´Ù.
1. Name of Procedure: ESD
2. Site of Tumor: Esophagus
3. Diagnosis: Large cell neuroendocrine carcinoma
4. WHO classification(2010): Neuroendocrine carcinoma
5. Multiplicity: Single
6. Size: 0.9x0.8 cm
7. Extent: Mucosa and submucosa
8. Grading: Mitotic Count: >20/10 HPF. Ki-67 labeling index: G3>20%
9. Immunohistochemical Stains - Synaptophysin : Positive, Chromogranin A: Positive, CD56: Positive, Ki-67: Positive (60%), PHH-3: Positive (198/10 HPFs)
10. Lymphovascular invasion: Present
11. Perineural invasion: Not identified
12. Resection Margins: Involved by tumor with cautery artifactsESD º´¸®. Á¡¸·ÃþÀº ºñ±³Àû intact Çѵ¥ ±× ¾Æ·¡·Î homogenousÇÑ ½Å°æ³»ºÐºñ¼¼Æ÷°¡ ³Ð°Ô º¸ÀÓ.
ESD º´¸®. ¶Ñ·ÇÇÑ endolymphatic emboli°¡ °üÂûµÇ¾úÀ½.
¼ö¼ú °á°ú¿¡¼´Â ¾Æ·¡¿Í °°ÀÌ lymph node metastasis°¡ ÀÖ¾ú½À´Ï´Ù. ¿ª½Ã ¼ö¼úÀ» º¸³»±â¸¦ Àß Çß´Ù°í »ý°¢ÇÏ¿´½À´Ï´Ù. »óºÎ½Äµµ º´¼ÒÀÎÁö¶ó ȯÀÚ²²¼ ¼ö¼ú ÈÄ °í»ýÀ» ¸¹ÀÌ Çϼ̽À´Ï´Ù.
Esophagus and upper stomach, Ivor Lewis operation:
; "LRLN", 0/2; "L9", 0/1; "L10", 0/1; "RD", 0/1; "5", 0/1; "7", 0/2; "8u", 0/1)
Status post endoscopic submucosal dissection (D13-7695)
No residual tumor
1) tumor size: cannot be determined (no residual tumor)
2) depth of invasion: cannot be determined (no residual tumor)
3) endolymphatic tumor emboli: not identified
4) perineural invasion: not identified
5) resection margins: free from carcinoma, safety margin: proximal, 1.5 cm ; distal, 18 cm ;
6) metastasis to 1 out of 25 regional lymph nodes (1/25: "LC omentum", 0/0; "G1", 0/3; "G2", 0/3; "G3", 0/8; "RRLN (right recurrent laryngeal nerve)", 1/2
7) treatment effect: not applicable
* Âü°í: EndoTODAY ½Äµµ SMT
¼Ò°ß: LB LC, antrum LC ¿Í AW¿¡ subcentimeterÀÇ multiple flat hyperemic lesion (ȤÀº red macule)µéÀÌ ÀÖ½À´Ï´Ù. ±ÙÁ¢ÇÏ¿© °üÂûÇÏ¿´À» ¶§ °¢ º´º¯Àº Á¡¸· Ç÷°üÀÌ È®ÀåµÈ ¾ç»óÀÔ´Ï´Ù.
Áø´Ü: Angiodysplasias
[ÀÌÁØÇà comment]
"Erosion°ú andiodysplasia¸¦ ¾î¶»°Ô ±¸ºÐÇϳª¿ä? ¾î¶² erosionÀº flat ÇÏ°í erythematousÇÏ°Ô º¸À̱⵵ Çϴµ¥¿ä..."¶ó´Â Áú¹®À» ¹Þ¾Ò½À´Ï´Ù. ¸Â½À´Ï´Ù. ErosionÀº µÎ °¡ÁöÀÔ´Ï´Ù. Flat erosion°ú elevated erosionÀÔ´Ï´Ù. Andiodysplasia´Â ÀÚ¼¼È÷ »ìÇǸé Ç¥¸éÀº Á¤»óÀÌ°í ±× ¾Æ·¡ÀÇ Ç÷°üÀÌ °¡Áö»óÀ¸·Î È®ÀåµÇ¾î ÀÖ°í ÁÖº¯ Á¡¸·ÀÌ ¾à°£ paleÇØ º¸ÀÔ´Ï´Ù (halo).
°£È¤ hemorrhagic gastritis¶ó°í ´äÇϽô ºÐÀÌ °è½Ê´Ï´Ù. Àú´Â 'ÃâÇ÷¼º À§¿°'À̶ó´Â ¿ë¾î¸¦ »ç¿ëÇÏÁö ¸»±â¸¦ ±ÇÇÕ´Ï´Ù. ÀÇ»çµéÀÌ¾ß °¡º±°Ô ºÙÀÌ´Â Áø´ÜÀÌÁö¸¸ ȯÀÚµéÀº ÃâÇ÷¼º À§¿°À̶ó´Â ¸»À» µè°Ô µÇ¸é º¸Åë ÀáÀ» ¼³Ä¡°Ô µË´Ï´Ù. ¡°ÃâÇ÷¼º À§¿°¡±À̶ó´Â ¸»À» µè°í ³ ÈÄ, ¿©·¯ º´¿øÀ» ÀüÀüÇϰųª ¿Â°® ÀÌ»óÇÑ Ä¡·á¸¦ ¹Þ´Â ºÐµéµµ ¸¹ÀÌ º¸¾Ò½À´Ï´Ù. ½ÇÁ¦·Î ÇÇ°¡ ÁÙÁÙ È帣°í ÀÖ´Â »óȲ ȤÀº Á¶±Ý Àü±îÁö ÁÙÁÙ ÇÇ°¡ ³ª¿À°í ÀÖ´ø »óȲÀÌ ¾Æ´Ï¶ó¸é 'ÃâÇ÷¼º À§¿°'À̶ó´Â Áø´Ü¸íÀ» ¾²Áö ¸¶½Ê½Ã¿ä. Àú´Â µü ÇÑ °¡Áö °æ¿ì¿¡¸¸ »ç¿ëÇÏ°í ÀÖ½À´Ï´Ù. RT (radiation treatment)-induced hemorrhagic gastritis°¡ ¹Ù·Î ±×·± °æ¿ìÀÔ´Ï´Ù.
¼Ò°ß: À§Ã¼ºÎ ÁÖ¸§ÀÌ ºÒ±ÔÄ¢ÇÏ°í tortuousÇÏ°Ô µÎ²¨¿öÁ® ÀÖÀ½. ÁÖ¸§ »çÀÌÀÇ °ñÂ¥±â °£°Ý°ú Á¡¸· µÎ²²´Â Á¤»óÀûÀÓ.
Áø´Ü: Hypertrophic gastritis
[ÀÌÁØÇà comment]
°¡Àå ¾î·Á¿î ¹®Á¦¿´´ø °Í °°½À´Ï´Ù. º¸¸¸ 4Çü ÁøÇ༺ À§¾ÏÀ̶ó°í ÁֽŠºÐÀÌ °¡Àå ¸¹¾Ò½À´Ï´Ù. °£È¤ varix¶ó°í ´äÇϽŠºÐµµ °è½Ê´Ï´Ù.^^ ±×·¯³ª Ç÷°üÀÌ ´Ã¾î³ °ÍÀº ¾Æ´Ï°í À§Á¡¸· ÁÖ¸§ÀÌ ºñÈÄµÈ °ÍÀ̳׿ä. EndoTODAY ºñÈļº À§¿°°ú EndoTODAY º¸¸¸ 4Çü ÁøÇ༺ À§¾Ï ºÎºÐÀ» Àß Àо½Ã´Â °ÍÀÌ ÁÁ°Ú½À´Ï´Ù.
2020-8-10. 8PM. EndoTODAY on Air
»çÁøÀ» º¸°í À§Ä¡ ÆľÇÀÌ ¾î·Æ´Ù´Â ÀÇ°ßÀÌ ÀÖ¾ú½À´Ï´Ù. ÁÂÃø »çÁøÀº À§Ã¼ÇϺΠ´ë¸¸ÀÌ°í ¿ìÃø »çÁøÀº ÀüÁ¤ºÎ¿¡¼ ¹Ù¶óº» À§°¢ÀÔ´Ï´Ù.
ÇÑ ¼±»ý´Ô²²¼ ´©±¸³ª °¡Áú ¼ö ÀÖ´Â ³»¿ë¿¡ ´ëÇÑ Áú¹®À» Áּ̽À´Ï´Ù. Á¦°¡ ´äº¯ÇÑ ³»¿ë°ú ÇÔ²² ¼Ò°³ÇÕ´Ï´Ù.
[2020-10-20. ¾Öµ¶ÀÚ Áú¹®]
AGC¶ó°í Àû±ä ÇßÁö¸¸ »ç½Ç È®½ÅÀº º°·Î ¾ø½À´Ï´Ù. Á¦°¡ °üÂûÇϱ⿡´Â fold°¡ µÎ²¨¿öÁ® Àִµ¥, fold°¡ ¾ø´Â ºÎºÐÀÎ angle(¿À¸¥ÂÊ »çÁøÀÌ angleÀÌ ¸Â´Ù´Â °¡Á¤ÀÔ´Ï´Ù) ÂÊÀÌ ÀϹÝÀûÀÎ ±¸Á¶¿Í ´Ù¸£°í Antrum ÂÊ¿¡ °¡±î¿öÁ®¼µµ Ç¥¸éÀÌ ¹º°¡ ºÒ±æÇÏ°Ô(?) »ý°å±â ¶§¹®¿¡ Àû¾ú½À´Ï´Ù. ÀÌ°Ô ¾ÏÀÌ ¸ÂÀ»±î¿ä? ÀÌ case´Â ´äÀÌ ÀÖÁö¸¸, ÀÏ¹Ý Áø·á ȯ°æ¿¡¼ ÀÌ·± case¿Í °°ÀÌ DDxÀÇ ¹«°Ô Â÷ÀÌ°¡ Å©°í ȯÀÚ°¡ °á°ú ¼³¸íÀ» µè°í ´À³¢´Â ºÎ´ãÀÌ Çϴðú ¶¥ Â÷ÀÌÀÏ ÅÙµ¥... ÀÌ·± °æ¿ì¿¡´Â ¾î¶»°Ô Áø·áÇϽôÂÁöµµ ±Ã±ÝÇÕ´Ï´Ù.
[2020-10-20. ÀÌÁØÇà ´äº¯]
1. angle ÁÖº¯ÀÇ fold°¡ ÀÌ»óÇÏ´Ù´Â °ÍÀº °¨À» Àß ÀâÀ¸¼Ì½À´Ï´Ù. ±×·±µ¥ angle ÁÖº¯±îÁö fold°¡ ÀÖ´Â ºÐµµ µå¹°Áö¸¸ °¡²û ¸¸³¯ ¼ö ÀÖ½À´Ï´Ù. ´Ù¸¸ fold°¡ ¾ø´Â ºÎºÐ¿¡¼µµ B4°¡ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ °æ¿ì´Â »õ·Î fold°¡ ¸¸µé¾îÁö´Â ¾ç»óÀÌ ¾Æ´Ï¶ó ¹Ô¹ÔÇÏ°Ô À§º®ÀÌ µÎ²¨¿öÁö´Â ¾ç»óÀ¸·Î B4°¡ ¹ß»ýÇÕ´Ï´Ù. ÁÖ¸§ ¾ø´Â °÷ÀÇ º¸¸¸ 4Çü ÁøÇ༺ À§¾Ï Áõ·Ê Çϳª¸¦ ¼Ò°³ÇÕ´Ï´Ù.
Stomach, subtotal gastrectomy: Advanced gastric carcinoma
1. Location : lower third, Center at body, antrum and lesser curvature
2. Gross type : Borrmann type 4
3. Histologic type : tubular adenocarcinoma, moderately differentiated
4. Histologic type by Lauren : intestinal
5. Size : 8x7.5 cm
6. Depth of invasion : invades serosa (pT4a)
7. Resection margin: free from carcinoma, safety margin: proximal 3 cm, distal 3.3 cm
8. Lymph node metastasis : metastasis to 9 out of 37 regional lymph nodes (pN3a) (perinodal extension: present) (9/37: "3", 4/13; "4", 0/5; "5", 0/0; "6", 0/4; "7", 0/2; "9", 1/3; "8a", 0/1, "11p", 0/0; "12a", 0/3; "4sb", 0/1; "1", 0/0; perigastric LN, 4/5)
9. Lymphatic invasion : present
10. Venous invasion : not identified
11. Perineural invasion : present
12. Peritoneal cytology : negative
13. AJCC stage by 7th edition: pT4a N3a2. 'AntrumÂÊ¿¡ °¡±î¿öÁ®¼µµ Ç¥¸éÀÌ ¹º°¡ ºÒ±æÇÏ°Ô »ý°å´Ù'´Â ºÎºÐÀº ÁÂÃø »çÁøÀÇ proximal stomach ºÎºÐÀ» ¸»¾¸ÇϽŠ°Í °°½À´Ï´Ù. ºÎµå·´Áö ¾Ê°í ¿ïÅüºÒÅüÇѵ¥ ¿©·¯ noduleµéÀÌ scattered µÈ °ÍÀº ¾Æ´ÏÁö¸¸ ... ¿©ÇÏÆ° Ç¥ÇöÇϽñ⠾î·Á¿î ÀÌ»óÀÌ ÀÖ½À´Ï´Ù. ºÒ±æÇÏ´Ù´Â ´À³¦À» ¹Þ¾Ò´Ù´Â °ÍÀ» ÀÌÇØÇÒ ¼ö Àְڳ׿ä.
3. ÁÂÃø »çÁøÀÇ ÇÏ´Ü lower body GCÀÇ fold°¡ ³¡³ª´Â ºÎºÐÀÇ fold°¡ µÎ²®°í ¹æÇâÀÌ ¾à°£ Á¦¸Ú´ë·ÎÀÎ Á¡µµ Àß ºÁ µÎ½Ã±â ¹Ù¶ø´Ï´Ù. B4´Â ÁÖ¸§ÀÌ µÎ²¨¿öÁöÁö¸¸ »ý°¢º¸´Ù linear, parallelÇÑ °æ¿ì°¡ ¸¹½À´Ï´Ù. Áö±×Àç±×·Î ²ªÀÌ´Â °ÍÀº ºñÈļº À§¿°¿¡¼ ´õ ÈçÇÕ´Ï´Ù.
4. ÀÓ»ó¿¡¼ º¸¸¸ 4ÇüÀÌ ÀǽɵǸé Àú´Â ³»½Ã°æÀ» ´Ù½Ã ÇÏ°í stomach protocolÀÇ CT¸¦ Âï½À´Ï´Ù. Stomach CT´Â À§¸¦ °ø±â³ª ¹°·Î ÆØâ½ÃÄѼ °Ë»çÇÏ´Â ¹æ¹ýÀÔ´Ï´Ù. ´ëºÎºÐÀÇ °æ¿ì´Â ³»½Ã°æ°ú stomach·Î ±¸ºÐÇÒ ¼ö ÀÖ½À´Ï´Ù.
³»½Ã°æ Á¶Á÷°Ë»ç´Â ¼ýÀÚ°¡ Áß¿äÇÏÁö ¾Ê°í À§Ä¡°¡ Áß¿äÇÕ´Ï´Ù. ¹Ì¶õÀ̳ª ±Ë¾çºÎºÐÀ» ã¾Æ¼ Á¤È®È÷ target biopsyÇÏ½Ã¸é »ý°¢º¸´Ù yield°¡ ÁÁ½À´Ï´Ù. ±×³É ¾Æ¹« °÷À̳ª »êźÃÑ ¹æ½ÄÀ¸·Î Á¶Á÷°Ë»ç¸¦ ÇÏ¸é ¾È µË´Ï´Ù. Á¶Á÷°Ë»ç¿¡¼ ¾ÏÀÌ ³ª¿ÀÁö ¾Ê´õ¶óµµ °·ÂÀÌ ÀÇ½ÉµÇ¸é ¼ö¼úÀ» ±ÇÇÏ´Â °ÍÀÌ ³´½À´Ï´Ù. ¹°·Ð ³»½Ã°æ°ú CT¸¦ short-term follow-upÀÌ ÇÊ¿ä¾ø´Ù´Â °ÍÀº ¾Æ´ÏÁö¸¸, ¸î °³¿ù ÈÄ °Ë»çÇÏ´Â °ÍÀº ÁÁÁö ¾Ê½À´Ï´Ù. ³»½Ã°æ¿¡¼ B4°¡ ÀǽɵǾú´Âµ¥ ¼ö¼úÀ» º¸³¾ Á¤µµ°¡ ¾Æ´Ï¶ó¸é Àû¾îµµ 1ÁÖÀÏ À̳»¿¡ Àç°Ë»çÇϽñ⠹ٶø´Ï´Ù. ´Ù¸¥ ºÐµéÀ» º¸¸é CEA³ª CA19-9°ú °°Àº tumor marker, PET-CT, EUSµµ ÀÌ¿ëÇϽô °Í °°½À´Ï´Ù. ±×·± °Ë»çµé(CEA³ª CA19-9°ú °°Àº tumor marker, PET-CT, EUS)Àº ºñÁ¤»óÀÏ ¶§´Â ³ª¸§ Àǹ̰¡ ÀÖÁö¸¸ Á¤»óÀ¸·Î ³ª¿À¸é °ÅÀÇ ¾Æ¹« Àǹ̵µ ¾ø½À´Ï´Ù. Tumor marker³ª PET-CT, EUS°¡ Á¤»óÀÎ B4´Â ¾ó¸¶µçÁö °¡´ÉÇÕ´Ï´Ù.
5. "ȯÀÚ°¡ °á°ú ¼³¸íÀ» µè°í ´À³¢´Â ºÎ´ãÀÌ Çϴðú ¶¥ Â÷ÀÌÀÏ ÅÙµ¥.." ºÎºÐÀº ¸Â´Â ¸»¾¸À̱â´Â ÇÏÁö¸¸ ¾ÏÀÌ ¾ÆÁÖ Á¶±ÝÀÌ¶óµµ ÀÇ½ÉµÇ¸é ±×³É ¾ÏÀÌ ÀÇ½ÉµÈ´Ù°í ¼ÖÁ÷ÇÏ°Ô ¸»¾¸µå¸®´Â °ÍÀÌ ³´½À´Ï´Ù. ¾Ï Áø´Ü °úÁ¤ÀÇ ¾î·Á¿ò°ú risk¿Í ½É¸®Àû ºÎ´ãÀº ȯÀÚ¿Í Àǻ簡 °øÀ¯ÇÏ´Â °ÍÀÔ´Ï´Ù. ȯÀÚ´Â ¾Æ¹« °Íµµ ¸ð¸£°í ¸¶³É ÇູÇÏ°Ô °è½Ã°í Àǻ縸 °í¹ÎÇÏ´Â »óȲÀ̶ó¸é Á¤È®ÇÑ Áø´ÜÀÌ ¾î·Æ½À´Ï´Ù. ±×³É µ¹Á÷±¸¸¦ ³¯¸®´Â °ÍÀÌ ÁÁ°Ú½À´Ï´Ù. ÀǽɵǸé ÀÇ½ÉµÈ´Ù°í ¸»ÇϽʽÿÀ. µ¹·Á¼ ¸»ÇÏÁö ¸» °ÍÀ» ±ÇÇÕ´Ï´Ù.
* Âü°í: EndoTODAY ºñÈļºÀ§¿°
¼Ò°ß: MB to LB, anteroLC side¿¡ 5cm Á¤µµÀÇ flat lesionÀÌ ÀÖ½À´Ï´Ù. º´º¯ÀÇ °æ°è´Â ¸íÈ®ÇÏÁö ¾ÊÀ¸¸ç Ç¥¸éÀº irregular, nodular, hyperremic, unevenÇÕ´Ï´Ù. º´º¯ÀÇ proximal part¿¡´Â Á¡¸· ÁÖ¸§ÀÌ ¾à°£ ²ø·Á¿À´Â °Íó·³ º¸ÀÌÁö¸¸ ¿ø·¡ ÀÖ´ø foldÀÎÁö ºñÁ¤»ó foldÀÎÁö ¸íÈ®ÇÏÁö ¾Ê½À´Ï´Ù.
Áø´Ü: EGC IIb
[ÀÌÁØÇà comment]
º´¼ÒÀÇ À§Ä¡¸¦ 'cardia'·Î Ç¥½ÃÇÑ ºÐÀÌ °è¼Ì½À´Ï´Ù. Cardia´Â GE junction Á÷ÇϺθ¸À» ¸»ÇÕ´Ï´Ù. º¸Åë 1-2cm Á¤µµ¸¸À» ÁöĪÇÕ´Ï´Ù. ±× ÀÌÇÏ´Â high body¶ó°í ºÎ¸£´Â °ÍÀÌ ÁÁ°Ú½À´Ï´Ù.
¾Õ¼ cardia´Â À½½ÄÀÌ µé¾î°¡´Â ¹®À̹ǷΠµé¹®, pylorus´Â À½½ÄÀÌ ³ª°¡´Â ¹®À̹ǷΠ³¯¹®À̶ó ºÎ¸¥´Ù°í ¼³¸íµå·È½À´Ï´Ù. ³»½Ã°æ¿¡¼ Á¤È®È÷ ¾îµð±îÁö¸¦ µé¹®ºÎ¶ó°í ºÎ¸¦Áö Á¤ÇØÁ®ÀÖÁö´Â ¾Ê½À´Ï´Ù. ±×·¸Áö¸¸ °ü·ÊÀûÀ¸·Î squamocolumnar junctionÀ¸·ÎºÎÅÍ 2 cm±îÁö¸¦ µé¹®ºÎ¶ó°í ºÎ¸£°í ÀÖ½À´Ï´Ù. À̺¸´Ù ´õ ¸Õ ºÎÀ§´Â À§Ã¼»óºÎ·Î ºÎ¸£´Â °ÍÀÌ Å¸´çÇÕ´Ï´Ù.
¼ö¼úÀ» ÇÏ¿´°í »ý°¢º¸´Ù º´ÀÌ ÄǽÀ´Ï´Ù. ³î¶øÁö¿ä?
Stomach, total gastrectomy:
Early gastric carcinoma
1. Location : middle third, Center at body and anterior wall
2. Gross type : EGC type IIb
3. Histologic type : signet-ring cell carcinoma
4. Histologic type by Lauren : diffuse
5. Size : 10 x 7 cm
6. Depth of invasion : invades submucosa (sm3) (pT1b)
7. Resection margin: free from carcinoma
8. Lymph node metastasis : no metastasis in 52 regional lymph nodes (pN0)
9. Lymphatic invasion : not identified
10. Venous invasion : not identified
11. Perineural invasion : not identified
12. Peritoneal cytology : negative
¼Ò°ß: Mid-antrum AW¿¡ 4cm Á¤µµÀÇ mass°¡ ÀÖ½À´Ï´Ù. º´º¯ÀÇ Áß¾Ó¿¡´Â ulcer°¡ ÀÖÀ¸¸ç marginÀº hyperemic, edematousÇÏ°í edge´Â spiculation µÇ¾î ÀÖ½À´Ï´Ù. º´º¯ ¹æÇ×À¸·Î fold°¡ ¿©·¯°³ ²ø·Á¿À´Â °ÍÀÌ °üÂûµË´Ï´Ù.
Áø´Ü: AGC, B-III
[ÀÌÁØÇà comment]
º´º¯ÀÇ ÁÖµÈ Æ¯Â¡À» ulcer·Î º¸°í EGC¶ó ´äÇÑ ºÐÀÌ °è¼Ì½À´Ï´Ù. º´º¯ÀÇ ÁÖµÈ Æ¯Â¡À» ulcer·Î º¸Áö ¸»°í mass·Î º¸°í, mass Áß¾Ó¿¡ ÀÛ°í ±íÀº ulcerationÀÌ ÀÖ´Ù°í º¸¸é ´õ ÁÁ°Ú½À´Ï´Ù. Áï, '±Ë¾ç 1cm + ÁÖº¯ ºÎÁ¾'À¸·Î º¸´Â °Íµµ ÁÁÁö¸¸ '4cm mass + Áß¾Ó ±Ë¾ç'À¸·Î º¸¸é ¾î¶²°¡ ÇÕ´Ï´Ù. ±×¸®°í fold ²÷±ä °÷ÀÇ À§Ä¡µµ Àß º¸¼¼¿ä.
ÁÖ(ñ«)¼Ò°ß, Áï major findingÀ» Á¤È®È÷ Àâ´Â °ÍÀº ¸Å¿ì Áß¿äÇÑ ÀÏÀÔ´Ï´Ù.
¼ö¼úÀ» ÇÏ¿´°í »ý°¢º¸´Ù ±í¾ú½À´Ï´Ù.
Stomach, subtotal gastrectomy:
. Advanced gastric carcinoma
1. Location : middle third, Center at body and anterior wall
2. Gross type : Borrmann type 3
3. Histologic type : signet-ring cell carcinoma
4. Histologic type by Lauren : diffuse
5. Size : 6.5x4.5 cm
6. Depth of invasion : penetrates subserosal connective tissue (pT3)
7. Resection margin: free from carcinoma, safety margin: proximal 2.5 cm, distal 3.5 cm
8. Lymph node metastasis : metastasis to 4 out of 67 regional lymph nodes (pN2), (perinodal extension: present)
9. Lymphatic invasion : present
10. Venous invasion : not identified
11. Perineural invasion : present
12. Peritoneal cytology : negative
13. AJCC stage by 7th edition: pT3 N2
[ºñ½ÁÇÑ Áõ·Ê (À§¾Ï 944]
P/D with signet ring cell component¶ó´Â Á¶Á÷°Ë»ç °á°ú¿Í ÇÔ²² ÀÇ·ÚµÈ ºÐÀÔ´Ï´Ù.
ÀÇ·Ú ÈÄ Àç°ËÀ» ÇÏ¿´°í °ÅÀÇ µ¿ÀÏÇÑ ¼Ò°ßÀÌ º¸¿´½À´Ï´Ù.
³»½Ã°æ ¼Ò°ßÀº focal wall-thickening mass with central ulceration and converging folds·Î ¿ä¾àÇÒ ¼ö ÀÖ½À´Ï´Ù.
¼ö¼úÀ» ½ÃÇàÇÏ¿´½À´Ï´Ù.
Focal wall thickeningÀ» º¸ÀÎ AGC¿´½À´Ï´Ù. Subserosal penetrationÀÌ ÀÖ¾úÀ¸³ª serosal invasionÀº ¾ø¾ú½À´Ï´Ù. ¸²ÇÁÀý ÀüÀÌ´Â ¾ø¾ú½À´Ï´Ù.
ÀϺΠÁ¡¸· ÇÔ¸ôºÎ¿¡¼´Â Ç¥¸é¿¡ ¾Ï¼¼Æ÷°¡ ³ëÃâµÇ¾ú½À´Ï´Ù.
´Ù¸¥ ºÎÀ§¿¡¼´Â foveolar epithelium ¹Ù·Î ¾Æ·¡ mid-to lower lamina propriaºÎÅÍ ¾Ï¼¼Æ÷°¡ º¸¿´½À´Ï´Ù. ³»½Ã°æ ¼Ò°ß¿¡¼ wall-thickening mass with central ulceration°ú ÀÏÄ¡ÇÏ´Â º´¸®¼Ò°ßÀÔ´Ï´Ù.
Áõ·Ê 35 - ´ëÀå, À§, ½ÊÀÌÁöÀåÀÔ´Ï´Ù.
¼Ò°ß: Cecum°ú proximal, transverse, descending colon¿¡ 5mm ÀÌÇÏÀÇ Is polypsµéÀÌ ¿©·¯°³ °üÂûµÇ°í ÀÖ½À´Ï´Ù. Stomach fundus¿¡ ¸¹Àº ¼öÀÇ Yamada-II polypµéÀÌ °üÂûµÇ°í ÀÖÀ¸¸ç duodenum second portion¿¡µµ ´Ù¼öÀÇ Yamada-II polypµéÀÌ °üÂûµÇ°í ÀÖ½À´Ï´Ù.
Áø´Ü: (1) FAP with colonic polyposis, gastric fundic gland polyposis and multiple small flat duodenal adenomas, (2) R/O Cowden syndrome, less likely
[ÀÌÁØÇà comment 1]
FAPÀÔ´Ï´Ù. ¼ö¼úÀ» ÇÏ¿´´Âµ¥ ´ëÀå ¼±Á¾ÀÌ 100°³´Â ÈξÀ ³Ñ¾ú½À´Ï´Ù. ÀýÁ¦Ç¥º»ÀÇ ÀϺÎÀÔ´Ï´Ù.
´ëÀåÀº sessile or (semi-)pedunculated adenomatous polypÀÌ°í, ½ÊÀÌÁöÀåÀº flat adenomatous polypÀÎ ¹Ý¸é, À§´Â non-adenomatous ¿ëÁ¾ÀÎ fundic gland polyposisÀÓ¿¡ ÁÖÀÇÇϽñ⠹ٶø´Ï´Ù.
³»½Ã°æ ¼Ò°ß¸¸ °¡Áö°í familialÀ̶ó´Â ¸»À» ¾µ ¼ö ÀÖ´ÂÁö Áú¹®ÀÌ ÀÖ¾ú½À´Ï´Ù. ¾Æ·¡¸¦ Âü°íÇϱ⠹ٶø´Ï´Ù.
¾Æ·¡ µ¿¿µ»ó°ú ÀÚ·áÁýÀ» ²À º¸½Ã±â ¹Ù¶ø´Ï´Ù.
* Âü°í: EndoTODAY FAP
[ÀÌÁØÇà comment 2]
FAP ȯÀÚ¿¡ Á¤È®È÷ ¸Â´Â °ÍÀº ¾Æ´ÏÁö¸¸, ´ëÀå³»½Ã°æ °Ë»ç¿¡¼ ¹ß°ßµÇ´Â ¿ëÁ¾À» ¾î¶»°Ô °ü¸®ÇÏ´ÂÁö Áú¹®ÀÌ ÀÖ¾ú½À´Ï´Ù. °¡´ÉÇϸé one stage·Î polypectomy¸¦ ÇÏ°í ÀÖ½À´Ï´Ù. ´ëÀå³»½Ã°æ µ¿ÀǼ¸¦ ¹ÞÀ» ¶§ ¿ëÁ¾ÀýÁ¦¼ú µ¿ÀǼ¸¦ ÇÔ²² ¹Þ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ¿ëÁ¾ÀÌ ³Ê¹« Å©°Å³ª ESD°¡ ÇÊ¿äÇÑ LSTÀÎ °æ¿ì, deep SM invasion cancer°¡ ÀǽɵǴ °æ¿ì µîÀº Á¶Á÷°Ë»ç¸¸ ÇÏ°í ÀýÁ¦¼úÀ» ´ÙÀ½ ±âȸ·Î ¹Ì·ç´Â °ÍÀÌ °¡´ÉÇÕ´Ï´Ù. À嵿°æ ±³¼ö´Ô²²¼´Â LST¿¡¼ Á¶Á÷°Ë»ç¸¦ ÇÏÁö ¾Ê°í ÀÇ·ÚÇصµ ÁÁ´Ù´Â °ßÇظ¦ ÁֽŠ¹Ù ÀÖÀ¸³ª, Àú´Â ¿ì¸®³ª¶ó Çö½Ç¿¡¼ '1-2°³ÀÇ Á¶Á÷°Ë»ç´Â ÇÊ¿äÇÏ´Ù'°í ¼³¸íÇß½À´Ï´Ù.
¾Æ·¡ ÀڷḦ Àо½Ç °ÍÀ» ±ÇÇÕ´Ï´Ù.
1) Àå õ°ø¿¡ ´ëÇÑ ¾Öµ¶ÀÚ Áõ·Ê ÆíÁö
2) PACS¿¡¼ ³»½Ã°æ »çÁøÀ» ¹Þ¾Æ Poweropint¿¡ ¿¹»Ú°Ô ³Ö´Â ¹æ¹ý
- PACS ȸéÀ¸·Î µé¾î°£´Ù.
- ¸¶¿ì½º ¿ìÃø buttonÀ» ´·¯¼ AnnotationÀ» NoneÀ¸·Î ¼±Á¤ÇÑ´Ù. À̶§ ¿ìÃø »ó´ÜÀÇ Á¤º¸´Â »ç¶óÁöÁö¸¸ ÁÂÃø »ó´ÜÀÇ Á¤º¸´Â »ç¶óÁöÁö ¾Ê´Â´Ù (Screencapture¹æ½ÄÀ¸·Î ¸¸µé¾îÁø fileÀ̱⠶§¹®).
- ¸¶¿ì½º ¿ìÃø buttonÀ» ´·¯¼ Export¸¦ ÇÑ´Ù. Àû´çÇÑ file À̸§À» ºÙÀδÙ. File À̸§¿¡´Â °³ÀÎÁ¤º¸°¡ µé¾î°¡Áö ¾Ê¾Æ¾ß ÇÑ´Ù.
- Powerpoint¿¡¼ ¿øÇÏ´Â »çÁøÀ» »ðÀÔÇÑ´Ù. À̶§ ¼±ÅÃÇÑ »çÁøµéÀÌ °ãÃļ º¸ÀδÙ.
- Powerpoint »ó´ÜÀÇ ºü¸¥½ÃÇà µµ±¸¸ðÀ½ÀÇ ¿ìÃø »ó´Ü¿¡ ÀÖ´Â ÀÚ¸£±â ±â´ÉÀ» ÀÌ¿ëÇÏ¿© »çÁøÀ» ÀÏÁ¤ÇÑ Å©±â·Î ÀÚ¸¥´Ù. ù »çÁøÀ» ÀÚ¸£°í ³ ÈÄ µÎ¹ø° »çÁøÀ» ÀÚ¸£¸é Àû´çÈ÷ µé·¯ºÙÀ¸¸é¼ Á¤È®È÷ °°Àº Å©±â°¡ µÈ´Ù.
- µµ±¸¸ðÀ½ ¿ì»ó´ÜÀÇ Å©±â ±â´ÉÀ» ÀÌ¿ëÇÏ¿© »çÁøÀÇ Å©±â¸¦ ³ôÀÌ 10cm·Î º¯°æÇÑ´Ù.
- »çÁøÀ» dragÇÏ¿© Àû´çÇÑ °÷¿¡ À§Ä¡½ÃŲ´Ù. °£È¤ ³ôÀÌ°¡ ¸ÂÁö ¾ÊÀ¸¸é µµ±¸¸ðÀ½ÀÇ Á¤·Ä - ¸ÂÃã - À§ÂÊ ¸ÂÃã ±â´ÉÀ» ÀÌ¿ëÇÏ¿© Á¤È®È÷ ³ôÀ̸¦ ¸ÂÃá´Ù.
2016-11-11. 2016/17 ³»½Ã°æ ±âÃÊ ±³À° ÇÁ·Î±×·¥ÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ¿À´Ã book-readingÀº ±èÅÂÁØ ¼±»ý´Ô²²¼ ÁöµµÇØ Áּ̽À´Ï´Ù. °¨»çÇÕ´Ï´Ù.
PDF 0.8 M. 2016-10-30. Àü°øÀÇ 3³âÂ÷ ¼±»ý´ÔµéÀÇ ´äº¯ÀÌ Á¡Á¡ ÁÁ¾ÆÁö°í ÀÖ½À´Ï´Ù. ¼ö°í ¸¹¾Ò½À´Ï´Ù. Àü°øÀÇ 3³âÂ÷ ÇÑ ºÐÀÇ ´äº¯ÀÔ´Ï´Ù.
2016-¸Þ¸ð¿Í ¸Þ¼¼Áö¸¦ ÀÌ¿ëÇÑ ±³À°. ÇÑ ¼±»ý´ÔÀ¸·ÎºÎÅÍ ¸ÞÀÏ·Î ´äº¯À» ¹ÞÀº ÈÄ ¸Þ¸ð¸¦ ½á¼ ¸Þ¼¼Áö·Î º¸³½ ÈÄ ¼öÁ¤µÈ ´äº¯À» ¿ä±¸ÇÏ¿´½À´Ï´Ù. µµ¿òÀÌ µÇ¾úÀ»Áö ¸ð¸£°ÚÀ¸³ª... ³Ê¹« pressure¸¦ ÁØ °Í °°¾Æ¼ ¹Ì¾ÈÇϱ⵵ ÇÏ°í... ¿©ÇÏÆ° »õ·Î¿î ½Ã´ë¿¡´Â »õ·Î¿î ±³À° ¹æ¹ýÀ» ½ÃµµÇØ¾ß ÇÑ´Ù°í »ý°¢ÇÕ´Ï´Ù.
2017-8-3. ¸Þ¼¼Áö·Î ´äÇϱâ. ¼Òȱ⳻°ú¸¦ Áö¿øÇÑ Àü°øÀÇ 3³âÂ÷ ¼±»ý´ÔµéÀ» ´ë»óÀ¸·Î ±³À°À» ½ÃÀÛÇß½À´Ï´Ù. º» ±³À°Àº 11¿ùºÎÅÍ ½ÃÇàÇÒ ¿¹Á¤Àε¥ ÀÏ´Ü description exercise °úÁ¤À» ÁøÇà ÁßÀÔ´Ï´Ù. È¿À²¼ºÀ» ³ôÀ̱â À§ÇÏ¿© ¸Þ¼¼Áö·Î ´äÇÏ´Â °ÍÀ» ½ÃµµÇß½À´Ï´Ù.
2024-5-19 DEX 5¿¡ ´ëÇÑ Ã·»è. »ó¼¼ÇÑ Çؼ³ ¸µÅ©µµ ÇÔ²² º¸³»°í ÀÖ½À´Ï´Ù.
© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng.